YAZ Rx

Select the drug indication to add to your list

YAZ

Acne
Contraception
Mood disorders
Only 4 drugs may be compared at once

Generic Name and Formulations:

Drospirenone 3mg, ethinyl estradiol 20micrograms (24 tabs); inert (4 tabs).

Select therapeutic use:

Indications for YAZ:

Moderate acne vulgaris in females ≥14 years of age, who have no known contraindications to oral contraceptive therapy, have achieved menarche, and desire contraception.

Adult:

1 tab daily for 28 days; repeat.

Children:

Premenarche: not recommended.

Contraindications:

Renal impairment. Adrenal insufficiency. High risk of arterial or venous thrombotic disease (eg, smokers or migraineurs over age 35, history of DVT or thromboembolism, cerebrovascular or coronary artery disease, thrombogenic valvular disease, atrial fibrillation, subacute bacterial endocarditis, hypercoagulopathies, uncontrolled hypertension, diabetes with vascular disease, headaches with focal neurologic symptoms). Breast or other estrogen or progestin-sensitive neoplasms. Hepatic disease or tumors. Undiagnosed abnormal uterine bleeding. Pregnancy.

Warnings/Precautions:

Discontinue if thrombotic event, unexplained visual changes, jaundice, or severe migraine occurs, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism. Hyperkalemia or risk thereof. Diabetes. Prediabetes. Uncontrolled dyslipidemias. Pregnancy-related cholestasis. History of depression; monitor and discontinue if serious depression recurs. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea. Do regular complete physical exams. Monitor BP; discontinue if significant rise occurs. May need barrier contraception with Sunday starts or postpartum use (see full labeling). Nursing mothers: not recommended.

Interactions:

Monitor serum K+ during 1st cycle with drugs that increase potassium (eg, ACE inhibitors, ARBs, NSAIDs, K+-sparing diuretics, K+ supplements, heparin, aldosterone antagonists); consider monitoring in high-risk patients taking concomitant long-term strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, voriconazole, indinavir, boceprevir, clarithromycin). May be antagonized by CYP3A4 or other enzyme inducers (eg, barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's wort, topiramate) (use backup contraception). May be affected by pro­tease inhibitors, NNRTIs, acetaminophen, ascorbic acid, itraconazole, ketoconazole. May antagonize lamotrigine. May affect laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). May need dose adjustment of thyroid hormones.

Pharmacological Class:

Progestin + estrogen.

Adverse Reactions:

Headache/migraine, hypertension, nausea, vomiting, breast pain/tenderness, fatigue, irritability, decreased libido, increased weight, affect lability, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, intolerance to contact lenses; increased risk of gallbladder disease, thromboembolic disorders.

Metabolism:

Hepatic (CYP3A4)

Elimination:

Fecal, renal.

Generic Availability:

YES

How Supplied:

Packs—3

YAZ 28 tablets of 3mg/0.02mg packages (Qty:1)

appx. price $124.00

Indications for YAZ:

Oral contraception.

Adult:

1 tab daily for 28 days; repeat.

Children:

Premenarche: not recommended.

Contraindications:

Renal impairment. Adrenal insufficiency. High risk of arterial or venous thrombotic disease (eg, smokers or migraineurs over age 35, history of DVT or thromboembolism, cerebrovascular or coronary artery disease, thrombogenic valvular disease, atrial fibrillation, subacute bacterial endocarditis, hypercoagulopathies, uncontrolled hypertension, diabetes with vascular disease, headaches with focal neurologic symptoms). Breast or other estrogen or progestin-sensitive neoplasms. Hepatic disease or tumors. Undiagnosed abnormal uterine bleeding. Pregnancy.

Warnings/Precautions:

Discontinue if thrombotic event, unexplained visual changes, jaundice, or severe migraine occurs, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism. Hyperkalemia or risk thereof. Diabetes. Prediabetes. Uncontrolled dyslipidemias. Pregnancy-related cholestasis. History of depression; monitor and discontinue if serious depression recurs. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea. Do regular complete physical exams. Monitor BP; discontinue if significant rise occurs. May need barrier contraception with Sunday starts or postpartum use (see full labeling). Nursing mothers: not recommended.

Interactions:

Monitor serum K+ during 1st cycle with drugs that increase potassium (eg, ACE inhibitors, ARBs, NSAIDs, K+-sparing diuretics, K+ supplements, heparin, aldosterone antagonists); consider monitoring in high-risk patients taking concomitant long-term strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, voriconazole, indinavir, boceprevir, clarithromycin). May be antagonized by CYP3A4 or other enzyme inducers (eg, barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's wort, topiramate) (use backup contraception). May be affected by pro­tease inhibitors, NNRTIs, acetaminophen, ascorbic acid, itraconazole, ketoconazole. May antagonize lamotrigine. May affect laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). May need dose adjustment of thyroid hormones.

Pharmacological Class:

Progestin + estrogen.

Adverse Reactions:

Headache/migraine, hypertension, nausea, vomiting, breast pain/tenderness, fatigue, irritability, decreased libido, increased weight, affect lability, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, intolerance to contact lenses; increased risk of gallbladder disease, thromboembolic disorders.

Metabolism:

Hepatic (CYP3A4)

Elimination:

Fecal, renal.

Generic Availability:

YES

How Supplied:

Packs—3

YAZ 28 tablets of 3mg/0.02mg packages (Qty:1)

appx. price $124.00

Indications for YAZ:

Treatment of premenstrual dysphoric disorder in women who choose an oral contraceptive as the method of birth control.

Adult:

1 tab daily for 28 days; repeat.

Children:

Premenarche: not recommended.

Contraindications:

Renal impairment. Adrenal insufficiency. High risk of arterial or venous thrombotic disease (eg, smokers or migraineurs over age 35, history of DVT or thromboembolism, cerebrovascular or coronary artery disease, thrombogenic valvular disease, atrial fibrillation, subacute bacterial endocarditis, hypercoagulopathies, uncontrolled hypertension, diabetes with vascular disease, headaches with focal neurologic symptoms). Breast or other estrogen or progestin-sensitive neoplasms. Hepatic disease or tumors. Undiagnosed abnormal uterine bleeding. Pregnancy.

Warnings/Precautions:

Discontinue if thrombotic event, unexplained visual changes, jaundice, or severe migraine occurs, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism. Hyperkalemia or risk thereof. Diabetes. Prediabetes. Uncontrolled dyslipidemias. Pregnancy-related cholestasis. History of depression; monitor and discontinue if serious depression recurs. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea. Do regular complete physical exams. Monitor BP; discontinue if significant rise occurs. May need barrier contraception with Sunday starts or postpartum use (see full labeling). Nursing mothers: not recommended.

Interactions:

Monitor serum K+ during 1st cycle with drugs that increase potassium (eg, ACE inhibitors, ARBs, NSAIDs, K+-sparing diuretics, K+ supplements, heparin, aldosterone antagonists); consider monitoring in high-risk patients taking concomitant long-term strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, voriconazole, indinavir, boceprevir, clarithromycin). May be antagonized by CYP3A4 or other enzyme inducers (eg, barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's wort, topiramate) (use backup contraception). May be affected by pro­tease inhibitors, NNRTIs, acetaminophen, ascorbic acid, itraconazole, ketoconazole. May antagonize lamotrigine. May affect laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). May need dose adjustment of thyroid hormones.

Pharmacological Class:

Progestin + estrogen.

Adverse Reactions:

Headache/migraine, hypertension, nausea, vomiting, breast pain/tenderness, fatigue, irritability, decreased libido, increased weight, affect lability, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, intolerance to contact lenses; increased risk of gallbladder disease, thromboembolic disorders.

Metabolism:

Hepatic (CYP3A4)

Elimination:

Fecal, renal.

Generic Availability:

YES

How Supplied:

Packs—3

YAZ 28 tablets of 3mg/0.02mg packages (Qty:1)

appx. price $124.00